Public lists: Pharma Startups (4732)

Neuromark is aiming to develop genetic answers for the new era in neuropsychiatry.

Neuromark is aiming to develop genetic answers for the new era in neuropsychiatry.

Company (Alive / Active)



336 Bon Air Center
Greenbrae, 94904
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Neuromark $0M Oct 17, 2018
See all 14 competitors

Web Traffic


Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Page Views Per Million (PVPM)
Reach Per Million

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Neuromark Jobs

jobs by Indeed job


Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.


Company Status Description Investors

AVEO Oncology

Cambridge, Massachusetts, United States
IPO / Went publicAVEO Oncology, formerly AVEO Pharmaceuticals, has built inducible, tissue-specific in vivo cancer models with which to discover drugs. Each model contains signature genetic mutations, and natural genetic variation akin to the genetic heterogeneity encountered across different primary tumors. Further, tumors that arise in this model have a number of differing phenotypes, including significant variation in tissue architecture and angiogenic potential.Login to see details

CytImmune Sciences

Rockville, Maryland, United States
Alive / ActiveCytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies. Based on an R&D strategy which harnesses the unique properties of gold nanoparticles, cytotoxic agents, and biology of tumors, the Company is developing a pipeline of drug candidates binding potent anti-cancer agents, whose toxicity profiles currently prevent or severely limit clinical use, to its patented colloidal gold t...Show allLogin to see details
See all 14 competitors


Title Application Date Patent Date Status
(Patent / Application)